Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer.

Drago JZ, Formisano L, Juric D, Niemierko A, Servetto A, Wander SA, Spring LM, Vidula N, Younger J, Peppercorn J, Yuen M, Malvarosa G, Sgroi D, Isakoff SJ, Moy B, Ellisen LW, Iafrate AJ, Arteaga CL, Bardia A.

Clin Cancer Res. 2019 Aug 1. doi: 10.1158/1078-0432.CCR-19-0138. [Epub ahead of print]

PMID:
31371343
2.

PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma.

Tanaka S, Batchelor TT, Iafrate AJ, Dias-Santagata D, Borger DR, Ellisen LW, Yang D, Louis DN, Cahill DP, Chi AS.

Acta Neuropathol Commun. 2019 Apr 29;7(1):66. doi: 10.1186/s40478-019-0720-8.

3.

Sacrificial Bioprinting of a Mammary Ductal Carcinoma Model.

Duchamp M, Liu T, van Genderen AM, Kappings V, Oklu R, Ellisen LW, Zhang YS.

Biotechnol J. 2019 Apr 9:e1700703. doi: 10.1002/biot.201700703. [Epub ahead of print]

PMID:
30963705
4.

Case-control analysis identifies shared properties of rare germline variation in cancer predisposing genes.

Artomov M, Joseph V, Tiao G, Thomas T, Schrader K, Klein RJ, Kiezun A, Gupta N, Margolin L, Stratigos AJ, Kim I, Shannon K, Ellisen LW, Haber D, Getz G, Tsao H, Lipkin SM, Altshuler D, Offit K, Daly MJ.

Eur J Hum Genet. 2019 May;27(5):824-828. doi: 10.1038/s41431-019-0346-0. Epub 2019 Feb 4.

PMID:
30718883
5.

Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq.

Karaayvaz M, Cristea S, Gillespie SM, Patel AP, Mylvaganam R, Luo CC, Specht MC, Bernstein BE, Michor F, Ellisen LW.

Nat Commun. 2018 Sep 4;9(1):3588. doi: 10.1038/s41467-018-06052-0.

6.

Developmental History Provides a Roadmap for the Emergence of Tumor Plasticity.

Tata PR, Chow RD, Saladi SV, Tata A, Konkimalla A, Bara A, Montoro D, Hariri LP, Shih AR, Mino-Kenudson M, Mou H, Kimura S, Ellisen LW, Rajagopal J.

Dev Cell. 2018 Mar 26;44(6):679-693.e5. doi: 10.1016/j.devcel.2018.02.024.

7.

Cognitive Computing to Guide Molecular-Based Therapy Selection: Steps Forward amid Abundant Need.

Ellisen LW.

Oncologist. 2018 Feb;23(2):145-146. doi: 10.1634/theoncologist.2017-0653. Epub 2018 Jan 12. No abstract available.

8.

Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer.

Matissek KJ, Onozato ML, Sun S, Zheng Z, Schultz A, Lee J, Patel K, Jerevall PL, Saladi SV, Macleay A, Tavallai M, Badovinac-Crnjevic T, Barrios C, Beşe N, Chan A, Chavarri-Guerra Y, Debiasi M, Demirdögen E, Egeli Ü, Gökgöz S, Gomez H, Liedke P, Tasdelen I, Tolunay S, Werutsky G, St Louis J, Horick N, Finkelstein DM, Le LP, Bardia A, Goss PE, Sgroi DC, Iafrate AJ, Ellisen LW.

Cancer Discov. 2018 Mar;8(3):336-353. doi: 10.1158/2159-8290.CD-17-0535. Epub 2017 Dec 14.

9.

Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.

Nagayama A, Ellisen LW, Chabner B, Bardia A.

Target Oncol. 2017 Dec;12(6):719-739. doi: 10.1007/s11523-017-0535-0. Review.

PMID:
29116596
10.

Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer.

Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R, Coopey S, Taghian A, Hughes KS, Isakoff SJ, Ellisen LW, Smith BL, Specht M, Moy B, Bardia A.

J Natl Compr Canc Netw. 2017 Oct;15(10):1216-1223. doi: 10.6004/jnccn.2017.0158.

PMID:
28982747
11.

A wound-healing program is hijacked to promote cancer metastasis.

Ellisen LW.

J Exp Med. 2017 Oct 2;214(10):2813-2815. doi: 10.1084/jem.20171556. Epub 2017 Sep 13.

12.

REDD1 induction regulates the skeletal muscle gene expression signature following acute aerobic exercise.

Gordon BS, Steiner JL, Rossetti ML, Qiao S, Ellisen LW, Govindarajan SS, Eroshkin AM, Williamson DL, Coen PM.

Am J Physiol Endocrinol Metab. 2017 Dec 1;313(6):E737-E747. doi: 10.1152/ajpendo.00120.2017. Epub 2017 Sep 12.

13.

A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer.

Polak P, Kim J, Braunstein LZ, Karlic R, Haradhavala NJ, Tiao G, Rosebrock D, Livitz D, Kübler K, Mouw KW, Kamburov A, Maruvka YE, Leshchiner I, Lander ES, Golub TR, Zick A, Orthwein A, Lawrence MS, Batra RN, Caldas C, Haber DA, Laird PW, Shen H, Ellisen LW, D'Andrea AD, Chanock SJ, Foulkes WD, Getz G.

Nat Genet. 2017 Oct;49(10):1476-1486. doi: 10.1038/ng.3934. Epub 2017 Aug 21.

PMID:
28825726
14.

Recurrent and functional regulatory mutations in breast cancer.

Rheinbay E, Parasuraman P, Grimsby J, Tiao G, Engreitz JM, Kim J, Lawrence MS, Taylor-Weiner A, Rodriguez-Cuevas S, Rosenberg M, Hess J, Stewart C, Maruvka YE, Stojanov P, Cortes ML, Seepo S, Cibulskis C, Tracy A, Pugh TJ, Lee J, Zheng Z, Ellisen LW, Iafrate AJ, Boehm JS, Gabriel SB, Meyerson M, Golub TR, Baselga J, Hidalgo-Miranda A, Shioda T, Bernards A, Lander ES, Getz G.

Nature. 2017 Jul 6;547(7661):55-60. doi: 10.1038/nature22992. Epub 2017 Jun 28.

15.

Bioprinting the Cancer Microenvironment.

Zhang YS, Duchamp M, Oklu R, Ellisen LW, Langer R, Khademhosseini A.

ACS Biomater Sci Eng. 2016 Oct 10;2(10):1710-1721. doi: 10.1021/acsbiomaterials.6b00246. Epub 2016 Jun 17.

16.

ACTL6A Is Co-Amplified with p63 in Squamous Cell Carcinoma to Drive YAP Activation, Regenerative Proliferation, and Poor Prognosis.

Saladi SV, Ross K, Karaayvaz M, Tata PR, Mou H, Rajagopal J, Ramaswamy S, Ellisen LW.

Cancer Cell. 2017 Jan 9;31(1):35-49. doi: 10.1016/j.ccell.2016.12.001. Epub 2016 Dec 29.

17.

Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis.

Spring LM, Gupta A, Reynolds KL, Gadd MA, Ellisen LW, Isakoff SJ, Moy B, Bardia A.

JAMA Oncol. 2016 Nov 1;2(11):1477-1486. doi: 10.1001/jamaoncol.2016.1897. Review.

18.

Women's Health Issues for BRCA Mutation Carriers.

Sabatini ME, Ellisen LW.

Am Soc Clin Oncol Educ Book. 2016;35:14-7. doi: 10.14694/EDBK_100001. No abstract available.

19.

ΔNp63α Silences a miRNA Program to Aberrantly Initiate a Wound-Healing Program That Promotes TGFβ-Induced Metastasis.

Rodriguez Calleja L, Jacques C, Lamoureux F, Baud'huin M, Tellez Gabriel M, Quillard T, Sahay D, Perrot P, Amiaud J, Charrier C, Brion R, Lecanda F, Verrecchia F, Heymann D, Ellisen LW, Ory B.

Cancer Res. 2016 Jun 1;76(11):3236-51. doi: 10.1158/0008-5472.CAN-15-2317. Epub 2016 Mar 17.

20.

Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence.

Keenan T, Moy B, Mroz EA, Ross K, Niemierko A, Rocco JW, Isakoff S, Ellisen LW, Bardia A.

J Clin Oncol. 2015 Nov 1;33(31):3621-7. doi: 10.1200/JCO.2015.62.2126. Epub 2015 Sep 14.

21.

Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.

Desmond A, Kurian AW, Gabree M, Mills MA, Anderson MJ, Kobayashi Y, Horick N, Yang S, Shannon KM, Tung N, Ford JM, Lincoln SE, Ellisen LW.

JAMA Oncol. 2015 Oct;1(7):943-51. doi: 10.1001/jamaoncol.2015.2690.

PMID:
26270727
22.

A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients.

Lincoln SE, Kobayashi Y, Anderson MJ, Yang S, Desmond AJ, Mills MA, Nilsen GB, Jacobs KB, Monzon FA, Kurian AW, Ford JM, Ellisen LW.

J Mol Diagn. 2015 Sep;17(5):533-44. doi: 10.1016/j.jmoldx.2015.04.009. Epub 2015 Jul 22.

PMID:
26207792
23.

A REDD1/TXNIP pro-oxidant complex regulates ATG4B activity to control stress-induced autophagy and sustain exercise capacity.

Qiao S, Dennis M, Song X, Vadysirisack DD, Salunke D, Nash Z, Yang Z, Liesa M, Yoshioka J, Matsuzawa S, Shirihai OS, Lee RT, Reed JC, Ellisen LW.

Nat Commun. 2015 Apr 28;6:7014. doi: 10.1038/ncomms8014.

24.

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.

Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, Garber JE, Ryan PD, Winer EP, Goss PE, Ellisen LW.

J Clin Oncol. 2015 Jun 10;33(17):1902-9. doi: 10.1200/JCO.2014.57.6660. Epub 2015 Apr 6.

25.

Yap tunes airway epithelial size and architecture by regulating the identity, maintenance, and self-renewal of stem cells.

Zhao R, Fallon TR, Saladi SV, Pardo-Saganta A, Villoria J, Mou H, Vinarsky V, Gonzalez-Celeiro M, Nunna N, Hariri LP, Camargo F, Ellisen LW, Rajagopal J.

Dev Cell. 2014 Jul 28;30(2):151-65. doi: 10.1016/j.devcel.2014.06.004. Epub 2014 Jul 17.

26.

Standardized decision support in next generation sequencing reports of somatic cancer variants.

Dienstmann R, Dong F, Borger D, Dias-Santagata D, Ellisen LW, Le LP, Iafrate AJ.

Mol Oncol. 2014 Jul;8(5):859-73. doi: 10.1016/j.molonc.2014.03.021. Epub 2014 Apr 4. Review.

27.

Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.

Wakimoto H, Tanaka S, Curry WT, Loebel F, Zhao D, Tateishi K, Chen J, Klofas LK, Lelic N, Kim JC, Dias-Santagata D, Ellisen LW, Borger DR, Fendt SM, Vander Heiden MG, Batchelor TT, Iafrate AJ, Cahill DP, Chi AS.

Clin Cancer Res. 2014 Jun 1;20(11):2898-909. doi: 10.1158/1078-0432.CCR-13-3052. Epub 2014 Apr 8.

28.

Mutational analysis and clinical correlation of metastatic colorectal cancer.

Russo AL, Borger DR, Szymonifka J, Ryan DP, Wo JY, Blaszkowsky LS, Kwak EL, Allen JN, Wadlow RC, Zhu AX, Murphy JE, Faris JE, Dias-Santagata D, Haigis KM, Ellisen LW, Iafrate AJ, Hong TS.

Cancer. 2014 May 15;120(10):1482-90. doi: 10.1002/cncr.28599. Epub 2014 Feb 5.

29.

Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.

Borger DR, Goyal L, Yau T, Poon RT, Ancukiewicz M, Deshpande V, Christiani DC, Liebman HM, Yang H, Kim H, Yen K, Faris JE, Iafrate AJ, Kwak EL, Clark JW, Allen JN, Blaszkowsky LS, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, Tanabe KK, Bardeesy N, Straley KS, Agresta S, Schenkein DP, Ellisen LW, Ryan DP, Zhu AX.

Clin Cancer Res. 2014 Apr 1;20(7):1884-90. doi: 10.1158/1078-0432.CCR-13-2649. Epub 2014 Jan 29.

30.

Basal cell signaling by p63 controls luminal progenitor function and lactation via NRG1.

Forster N, Saladi SV, van Bragt M, Sfondouris ME, Jones FE, Li Z, Ellisen LW.

Dev Cell. 2014 Jan 27;28(2):147-60. doi: 10.1016/j.devcel.2013.11.019. Epub 2014 Jan 9.

31.

Inactivation of the tumor suppressor WTX in a subset of pediatric tumors.

Akhavanfard S, Vargas SO, Han M, Nitta M, Chang CB, Le LP, Fazlollahi L, Nguyen Q, Ma Y, Cosper A, Dias-Santagata D, Han JY, Bergethon K, Borger DR, Ellisen LW, Pomeroy SL, Haber DA, Iafrate AJ, Rivera MN.

Genes Chromosomes Cancer. 2014 Jan;53(1):67-77. doi: 10.1002/gcc.22118. Epub 2013 Nov 5.

PMID:
24249259
32.

FGFR2 signaling underlies p63 oncogenic function in squamous cell carcinoma.

Ramsey MR, Wilson C, Ory B, Rothenberg SM, Faquin W, Mills AA, Ellisen LW.

J Clin Invest. 2013 Aug;123(8):3525-38. doi: 10.1172/JCI68899. Epub 2013 Jul 8.

33.

Mutation frequency in 15 common cancer genes in high-risk head and neck squamous cell carcinoma.

McBride SM, Rothenberg SM, Faquin WC, Chan AW, Clark JR, Ellisen LW, Wirth LJ.

Head Neck. 2014 Aug;36(8):1181-8. doi: 10.1002/hed.23430. Epub 2014 Mar 10.

34.

Personalized medicine: hype or reality.

Chabner BA, Ellisen LW, Iafrate AJ.

Oncologist. 2013 Jun;18(6):640-3. doi: 10.1634/theoncologist.2013-0210. No abstract available.

35.

BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults.

Chi AS, Batchelor TT, Yang D, Dias-Santagata D, Borger DR, Ellisen LW, Iafrate AJ, Louis DN.

J Clin Oncol. 2013 May 10;31(14):e233-6. doi: 10.1200/JCO.2012.46.0220. Epub 2013 Apr 1. No abstract available.

PMID:
23547069
36.

Young adult daughters of BRCA1/2 positive mothers: what do they know about hereditary cancer and how much do they worry?

Patenaude AF, Tung N, Ryan PD, Ellisen LW, Hewitt L, Schneider KA, Tercyak KP, Aldridge J, Garber JE.

Psychooncology. 2013 Sep;22(9):2024-31. doi: 10.1002/pon.3257. Epub 2013 Feb 18.

PMID:
23417902
37.

Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.

He L, Torres-Lockhart K, Forster N, Ramakrishnan S, Greninger P, Garnett MJ, McDermott U, Rothenberg SM, Benes CH, Ellisen LW.

Cancer Discov. 2013 Mar;3(3):324-37. doi: 10.1158/2159-8290.CD-12-0417. Epub 2012 Dec 28.

38.

ΔNp63α represses anti-proliferative genes via H2A.Z deposition.

Gallant-Behm CL, Ramsey MR, Bensard CL, Nojek I, Tran J, Liu M, Ellisen LW, Espinosa JM.

Genes Dev. 2012 Oct 15;26(20):2325-36. doi: 10.1101/gad.198069.112. Epub 2012 Sep 26.

39.

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.

Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J, Rodríguez O, Calvo MT, Aura C, Díez O, Rubio IT, Pérez J, Rodón J, Cortés J, Ellisen LW, Scaltriti M, Baselga J.

Cancer Discov. 2012 Nov;2(11):1036-47. doi: 10.1158/2159-8290.CD-11-0348. Epub 2012 Aug 22.

40.

The molecular pathogenesis of head and neck squamous cell carcinoma.

Rothenberg SM, Ellisen LW.

J Clin Invest. 2012 Jun;122(6):1951-7. Review.

41.

Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.

Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, Schenkein DP, Hezel AF, Ancukiewicz M, Liebman HM, Kwak EL, Clark JW, Ryan DP, Deshpande V, Dias-Santagata D, Ellisen LW, Zhu AX, Iafrate AJ.

Oncologist. 2012;17(1):72-9. doi: 10.1634/theoncologist.2011-0386. Epub 2011 Dec 16.

42.

mTOR activity under hypoxia.

Vadysirisack DD, Ellisen LW.

Methods Mol Biol. 2012;821:45-58. doi: 10.1007/978-1-61779-430-8_4.

43.

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.

Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, Lennes IT, Digumarthy S, Waltman BA, Bast E, Tammireddy S, Morrissey L, Muzikansky A, Goldberg SB, Gainor J, Channick CL, Wain JC, Gaissert H, Donahue DM, Muniappan A, Wright C, Willers H, Mathisen DJ, Choi NC, Baselga J, Lynch TJ, Ellisen LW, Mino-Kenudson M, Lanuti M, Borger DR, Iafrate AJ, Engelman JA, Dias-Santagata D.

Ann Oncol. 2011 Dec;22(12):2616-24. doi: 10.1093/annonc/mdr489. Epub 2011 Nov 9.

44.

Notch signaling mediates p63-induced quiescence: a new facet of p63/Notch crosstalk.

Forster N, Ellisen LW.

Cell Cycle. 2011 Nov 1;10(21):3632-3. doi: 10.4161/cc.10.21.18182. Epub 2011 Nov 1. No abstract available.

45.

Feedback control of p53 translation by REDD1 and mTORC1 limits the p53-dependent DNA damage response.

Vadysirisack DD, Baenke F, Ory B, Lei K, Ellisen LW.

Mol Cell Biol. 2011 Nov;31(21):4356-65. doi: 10.1128/MCB.05541-11. Epub 2011 Sep 6.

46.

Circadian function in cancer: regulating the DNA damage response.

Ramsey MR, Ellisen LW.

Proc Natl Acad Sci U S A. 2011 Jun 28;108(26):10379-80. doi: 10.1073/pnas.1107319108. Epub 2011 Jun 14. No abstract available.

47.

Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma.

Ramsey MR, He L, Forster N, Ory B, Ellisen LW.

Cancer Res. 2011 Jul 1;71(13):4373-9. doi: 10.1158/0008-5472.CAN-11-0046. Epub 2011 Apr 28.

49.

PARP inhibitors in cancer therapy: promise, progress, and puzzles.

Ellisen LW.

Cancer Cell. 2011 Feb 15;19(2):165-7. doi: 10.1016/j.ccr.2011.01.047.

50.

A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma.

Ory B, Ramsey MR, Wilson C, Vadysirisack DD, Forster N, Rocco JW, Rothenberg SM, Ellisen LW.

J Clin Invest. 2011 Feb;121(2):809-20. doi: 10.1172/JCI43897. Erratum in: J Clin Invest. 2014 Mar 3;124(3):1418.

Supplemental Content

Loading ...
Support Center